Related Experiment Video

Updated: Jun 19, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies

Hanxiao Shi1, Yiqian Feng1, Tao Guo1

  • 1Department of the First Clinical Medicine, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.

Breast Cancer (Dove Medical Press)
|June 18, 2026
PubMed

Insights

Human epidermal growth factor receptor 2 (HER2) heterogeneity complicates breast cancer assessment and targeted therapy. New strategies aim to overcome these challenges for better patient stratification and precision treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Human epidermal growth factor receptor 2 (HER2) is a critical factor in breast cancer development.
  • Significant HER2 heterogeneity exists across temporal, spatial, and molecular dimensions.
  • This heterogeneity poses challenges for accurate HER2 assessment and effective targeted therapy.

Purpose of the Study:

  • To review current HER2 testing standards and their limitations.
  • To explore the multifaceted nature and biological drivers of HER2 heterogeneity.
  • To discuss emerging diagnostic and therapeutic strategies addressing HER2 heterogeneity.

Main Methods:

  • Literature review of current HER2 testing methodologies.
  • Analysis of studies detailing HER2 heterogeneity manifestations and mechanisms.
  • Examination of novel diagnostic and therapeutic approaches for HER2-positive breast cancer.

Main Results:

  • Current HER2 testing methods have inherent limitations due to heterogeneity.
  • HER2 heterogeneity presents multidimensional challenges impacting treatment efficacy.
  • Emerging strategies show promise in addressing HER2 heterogeneity.

Conclusions:

  • Addressing HER2 heterogeneity is crucial for improving breast cancer patient outcomes.
  • Optimizing patient stratification and precision treatment requires understanding HER2 heterogeneity.
  • Further research into novel diagnostics and therapeutics is warranted.
Keywords:
breast carcinomadrug resistancehuman epidermal growth factor receptor 2 heterogeneitytargeted therapy

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...